OCUL vs NVCR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). Analysts rate Ocular Therapeutix, Inc. (OCUL) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ocular Therapeutix, Inc.

(OCUL) delivered a total return of -40. 4%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus OCUL's -10. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ocular Therapeutix, Inc.

(OCUL) is the lower-risk stock at 1. 27β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 74% more volatile than OCUL relative to the S&P 500. On balance sheet safety, Ocular Therapeutix, Inc. (OCUL) carries a lower debt/equity ratio of 12% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -16. 4% for Ocular Therapeutix, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NovoCure Limited (NVCR) is the more profitable company, earning -20.

8% net margin versus -513. 2% for Ocular Therapeutix, Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -521. 0% for OCUL. At the gross margin level — before operating expenses — OCUL leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ocular Therapeutix, Inc.

(OCUL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OCUL: -10. 6%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.